Mangoceuticals plans up to $10M Series D preferred Reg A offering; annual meeting set for Dec 30

MANGOCEUTICALS, INC.

Series B holder (all 50 shares) consented Nov 2, 2026 to 8% Series D Convertible Cumulative Preferred; up to 1,000,000 shares at $10.00 each via Regulation A offering.
Neither the Series B Amendment nor the Series D certificate of designations has been filed with the Texas Secretary of State; neither is effective and the Company may not proceed.
Series B Amendment recognizes Series D's senior dividend and liquidation rights and is limited to approving the Series D designation only.
Combined 2025 and 2026 annual meeting set for Dec 30, 2026 at Dallas offices; record date Nov 12, 2026; shareholder proposals due Nov 16, 2026.
No sales in the contemplated Regulation A offering will occur before the SEC qualifies the Form 1-A offering statement.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.